Clinical Trials Logo

Malignant Melanoma clinical trials

View clinical trials related to Malignant Melanoma.

Filter by:

NCT ID: NCT00135408 Completed - Malignant Melanoma Clinical Trials

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.

NCT ID: NCT00111696 Completed - Malignant Melanoma Clinical Trials

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Start date: May 2005
Phase: Phase 1
Study type: Interventional

To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.

NCT ID: NCT00087776 Completed - Malignant Melanoma Clinical Trials

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

Start date: October 2002
Phase: N/A
Study type: Interventional

The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.

NCT ID: NCT00086489 Completed - Malignant Melanoma Clinical Trials

CP-675,206 In Patients With Advanced Melanoma

Start date: August 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma

NCT ID: NCT00044356 Completed - Melanoma Clinical Trials

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Start date: February 2001
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

NCT ID: NCT00039000 Completed - Malignant Melanoma Clinical Trials

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery but who receive conventional chemotherapy including IL-2/DTIC. A second goal is to determine the safety and frequency of side effects in subjects who receive therapy with HSPPC-96.

NCT ID: NCT00034554 Completed - Malignant Melanoma Clinical Trials

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Start date: March 2002
Phase: Phase 1
Study type: Interventional

Up to 24 patients with stage III or stage IV melanoma will be enrolled. Patients who are currently disease-free but at high risk for relapse are also eligible. Patients will receive vaccinations of gp75 at assigned dose levels. Patients who exhibit serologic and stable/clinical response are eligible to receive booster vaccinations. Patients will be evaluated for safety and efficacy throughout the duration of the study. In this study, the optimal biologically effective dose is defined as the lowest dose of gp75 that results in the production of anti-gp75 antibodies.